FIMI's Ishay Davidi Novolog completes TASE IPO

High demand meant that the pharma logistics company's valuation for the public stage of the offering rose to NIS 560 million.

Prof. Yitzhak Haviv Photo: Amir Meiri "Sometimes saving lives justifies crony capitalism"

Bar-Ilan University biologist Prof. Izhak Haviv insists personalized medicine to cure cancer in affluent people will help all patients.

medicine, healthcare MindUP incubator takes in first startup

Hemonitor measures blood flow in the main artery of intensive care patients.

Nasdaq  picture: Bloomberg Nasdaq expects more Israeli IPOs in 2017

94 Nasdaq-listed Israeli companies have an aggregate $70 billion market cap.

medical cannabis Kalytera buys Israeli cannabis co Talent Biotech

The Canadian therapeutics firm will pay $10 million plus shares and $20 million in milestone payments for the Israeli GvHD treatment developer.

Copaxone Teva boosted as FDA delays generic Copaxone

IBI analyst Steven Tepper: Every month of delay means $150-200 million more for Teva.

Novolog truck  photo: Company website Novolog flotation underway

Drug distributor Novolog has a 40% share of the Israeli market.

Teva  photo: Reuters Teva's drug pipeline could contain blockbusters

Life after Copaxone: Teva is expecting the results of five clinical trials this year likely to gain FDA approval.

Protalix O'Connor fund owns 9.5% of Protalix Biotherapeutics

Protalix's share price has shot up 300% after plunging following a debt settlement in December.

Teva Photo: Tamar Matsafi US funds raised Teva stakes in Q4

Fidelity reduced its holding, but three other funds bought shares to the tune of $3 billion.

dentistry image: Shutterstock/ASAP Creative Israeli dental tech cos lead in implant innovations

Poalim Capital Markets: We want to help the Israel medical market mature into a global leader.

Erez Vigodman Photo: Eyal Yizhar Teva's outgoing CEO earned NIS 20m in 2016

Teva's five highest-paid executives earned an aggregate $25 million.

biomed JDRF T1D Fund invests in glucose sensor co GluSense

The Israeli company is developing a long lasting injectable glucose sensor for treatment of Type 1 diabetes.

Biomed (Illustration: Shutterstock) DayTwo teams with J&J on diagnostics

DayTwo provides personalized dietary recommendations according to an intestinal bacteria profile.

Teva Photo: Tamar Matsafi Teva mulls splitting generic, branded businesses

Most analysts are lukewarm or negative about Teva, citing its debt and uncertainty about the new CEO.

Shimon Eckhouse Syneron seeks buyer for $322m

Apax Partners is among those interested in the Israeli esthetic medicine company.

Yitzhak Peterburg Teva Q4 results provide badly needed boost

The Israeli pharmaceuticals company saw its share price jump after its financial results beat the analysts and it reaffirmed its 2017 guidance.

Teva Teva campus construction to continue despite cost

The Ra'anana campus will house Teva's headquarters, laboratories, and production facilities.

Materna  photo: Nina Epstein Maabarot selling remaining Materna shares

Maabarot will post a NIS 400-450 million capital gain on the exercise of its option.

Avi Yaron Photo: PR $50m Israeli fund to invest in neuro wellness

JOY Ventures, a new investment firm, has inaugurated offices in Herzliya, set up an incubator and will invest in startups, and research.

Erez Vigodman, Benny Landa Photos: Eyal Yizhar Landa: Teva needs CEO with pharma background

Activist shareholder Benny Landa thinks Teva should be split into generics and branded drugs companies.

Arie Belldegrun Photo: PR "Teva slow to prepare for life after Copaxone"

Kite Pharma CEO Arie Belldegrun, who resigned from Teva's board: Teva's pipeline provides sufficient infrastructure to make it a significant innovative player.

Erez Vigodman photo: Eyal Yitzhar Debt weighs on Teva

On top of all its other woes, the Israeli pharmaceutical giant has a net debt of $35 billion, higher than its $32 billion market cap.

Kira Radinsky and Morris Kahn Photos: E.Yizhar, PR Predictive analytics health research institute set up

The Israeli institute has already developed technology for predicting colon cancer among Maccabi Health Fund patients.

Orcam Photo: PR Liberating the visually impaired

Israeli company OrCam has a discreet device that attaches to eyeglasses and reads aloud any text the wearer points to.

Erez Vigodman  photo: Tamar Matsafi Chaim Hurvitz: Teva has no problem as a company

Some analysts see distress signals in Teva's 2017 outlook, but most still recommend "Buy".

Erez Vigodman photo: Eyal Yitzhar Teva strives to pull out of a tailspin

CEO Erez Vigodman retains the board's support even though the company's share has lost half its value.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2016